	US 12,453,772 B2
	Targeting the PVR axis using CAR T cell therapy and combinations
AJ Robert McGray, Hamilton (CN); and Jessie Chiello, West Seneca, NY (US)
Assigned to Roswell Park Cancer Institute Corporation, Buffalo, NY (US)
Filed by Roswell Park Cancer Institute Corporation, Buffalo, NY (US)
Filed on Dec. 23, 2024, as Appl. No. 18/999,456.
Claims priority of provisional application 63/614,125, filed on Dec. 22, 2023.
Prior Publication US 2025/0205336 A1, Jun. 26, 2025
Int. Cl. A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/33 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01)

CPC A61K 40/11 (2025.01) [A61K 40/31 (2025.01); A61K 40/33 (2025.01); A61K 40/4202 (2025.01); A61K 40/421 (2025.01); A61P 35/00 (2018.01)]

11 Claims

1. A method of treating ovarian cancer in an individual by administering to the individual modified T cells, wherein the modified T cells are modified i) to express a chimeric antigen receptor (CAR), the CAR comprising a T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (TIGIT) extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3ζ segment; and ii) to express and secrete a Bi-specific T cell engager (BiTE), wherein the BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FRα) and a segment that that can specifically bind to a human CD3ε segment.